Intervention
Dasatinib plus quercetin
Research Observatory
Evidence Update
Current evidence
For dasatinib plus quercetin, the accepted bone-trial primary null remains. A corrected independent kidney-disease pilot supports only limited tissue-specific target engagement.
What changed
Adds the corrigendum: adipose evidence persisted; the original skin-significance conclusion did not.
What did not change
No established fracture prevention, kidney benefit or human longevity effect.
Why it matters
Senolytic target markers are not demonstrated clinical benefit.
Main limitation
Small uncontrolled pilot with corrected paired analyses and tissue-specific findings; target engagement is not clinical efficacy.
Next proof
Independent controlled mechanistic and clinical studies.
Summary
The accepted bone-trial primary null remains. A corrected independent kidney-disease pilot supports only limited tissue-specific target engagement.
Intelligence Take
Senolytic target markers are not demonstrated clinical benefit.
Limitations
Small uncontrolled pilot with corrected paired analyses and tissue-specific findings; target engagement is not clinical efficacy.